Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Due to the COVID-19 pandemic, the global Kidney Cancer Drugs market size is estimated to be worth US$ 3970.1 million in 2022 and is forecast to a readjusted size of US$ 5501.9 million by 2030 with a CAGR of 4.3% during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Kidney Cancer Drugs market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Kidney Cancer Drugs landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.
This report focuses on Kidney Cancer Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Kidney Cancer Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Kidney Cancer Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2018 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Angiogenesis Inhibitors
mTOR Inhibitors
Monoclonal Antibodies
Cytokine Immunotherapy (IL-2)
Segment by Application
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bayer
Roche
GlaxoSmithKline
Novartis
Pfizer
Abbott Laboratories
Active Biotech
Amgen
Argos Therapeutics
ArQule
AVEO Pharmaceuticals
Bionomics
Bristol-Myers Squibb
Cerulean Pharma
Exelixis
Genentech
immatics biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
